Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 15/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PASK | Q96RG2 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14819609 | 0.92 | CACNA1H (0.42) | CACNA1HNOTUMPDE1CTRPV1CACNA1G | |
| SCHEMBL14819568 | 0.90 | CACNA1H (0.44) | CACNA1HNOTUMPDE1CTRPV1CACNA1G | |
| SCHEMBL14819393 | 0.90 | NOTUM (0.46) | CACNA1HNOTUMPDE1CCACNA1GCACNA1I | |
| SCHEMBL14819778 | 0.89 | CACNA1H (0.44) | CACNA1HNOTUMPDE1C | |
| SCHEMBL14819612 | 0.86 | CACNA1H (0.38) | CACNA1HNOTUMPDE1CTRPV1 | |
| SCHEMBL14819398 | 0.84 | MAPT (0.42) | CACNA1HCACNA1GCACNA1I | |
| SCHEMBL14819412 | 0.83 | NOTUM (0.39) | NOTUMTRPV1 | |
| SCHEMBL14805147 | 0.83 | NOTUM (0.48) | CACNA1HNOTUMPDE1CTRPV1CCNC | |
| SCHEMBL14819279 | 0.83 | CACNA1H (0.43) | CACNA1HNOTUMCACNA1GCACNA1I | |
| SCHEMBL14819764 | 0.83 | NPC1 (0.41) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | CACNA1H 3395/4885NOTUM 4051/4885PDE1C 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.